Form 4: ImmunityBio Director Sells Shares Under 10b5-1 Plan

ImmunityBio, Inc. Director Christobel Selecky reported transactions involving the acquisition and sale of common stock, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director Christobel Selecky acquired 35,064 shares of common stock at $2.98 per share and an additional 124,414 shares at $2.99 per share on July 1, 2026.
• On the same date, Selecky sold a total of 159,478 shares, which represents the sum of the acquired shares, at a weighted average price of $9.0236 per share, ranging from $9.00 to $9.07.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on March 13, 2026, which is designed to comply with affirmative defense conditions for insider trading.
• Following these transactions, Selecky's direct beneficial ownership of common stock is reported as 0 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by a director can be a negative signal, the execution under a Rule 10b5-1 plan and the profitable nature of the transactions under that plan temper this concern.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider-trading-related sales.
• The sales occurred at a significantly higher price ($9.00-$9.07) compared to the acquisition price ($2.98-$2.99), suggesting a profitable execution of the plan.

Negatives

• A significant number of shares were sold by a director, which could be perceived negatively by the market.
• The director's direct beneficial ownership has been reduced to zero following these transactions.

Risks

• Potential for negative market perception due to a director selling a substantial number of shares.
• The effectiveness and continued validity of the Rule 10b5-1 plan in the face of market volatility or regulatory scrutiny.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.
• Represents the weighted average share price of an aggregate total of 159,478 shares sold in the price range of $9.00 to $9.07 by the Reporting Person.
• The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the 'Issuer') or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions are common for publicly traded companies. The use of a Rule 10b5-1 plan by a director of ImmunityBio, Inc. (IBRX) suggests a structured approach to managing personal stock holdings, often employed to diversify or meet financial obligations without triggering insider trading concerns. The significant price difference between acquisition and sale under the plan highlights potential for profitable transactions within the biotech sector.

Comparison to Industry Standards

• Industry standard practice for directors often involves establishing Rule 10b5-1 plans to manage stock sales, especially when facing liquidity needs or diversification goals.
• The profit margin realized in this transaction ($9.0236 sale price vs. $2.98-$2.99 acquisition price) is a positive indicator for the execution of the plan, though specific industry benchmarks for director transaction profitability are not publicly available.
• The sale of all directly held shares by a director is a notable event, though the context of a pre-arranged plan mitigates concerns compared to an unannounced sale.

Stakeholder Impact

• Shareholders: May view the director's sale of all directly held shares with some concern, although the Rule 10b5-1 plan provides context that it was pre-planned.
• Management: The execution of the 10b5-1 plan by a director demonstrates adherence to corporate governance best practices for insider trading.
• Regulatory Bodies: The filing itself is a compliance action, ensuring transparency as required by the SEC.

Next Steps

• The reporting person may be required to provide further details on individual sale prices upon request from regulatory bodies or security holders.
• Future Form 4 filings will indicate any new beneficial ownership or transactions by the reporting person.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Beneficial Ownership, Director Transactions, ImmunityBio, IBRX, SEC Filing